FibroGen (FGEN) Competitors $0.35 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FGEN vs. IXHL, SGMT, PBYI, SKYE, TELO, VTYX, RPTX, CNTX, MCRB, and GLPGShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Incannex Healthcare (IXHL), Sagimet Biosciences (SGMT), Puma Biotechnology (PBYI), Skye Bioscience (SKYE), Telomir Pharmaceuticals (TELO), Ventyx Biosciences (VTYX), Repare Therapeutics (RPTX), Context Therapeutics (CNTX), Seres Therapeutics (MCRB), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry. FibroGen vs. Incannex Healthcare Sagimet Biosciences Puma Biotechnology Skye Bioscience Telomir Pharmaceuticals Ventyx Biosciences Repare Therapeutics Context Therapeutics Seres Therapeutics Galapagos FibroGen (NASDAQ:FGEN) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership. Do analysts rate FGEN or IXHL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of FGEN or IXHL? 72.7% of FibroGen shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 2.0% of FibroGen shares are held by insiders. Comparatively, 26.5% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is FGEN or IXHL more profitable? Incannex Healthcare has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Incannex Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-67.66% N/A -36.17% Incannex Healthcare N/A -182.23%-127.38% Does the MarketBeat Community believe in FGEN or IXHL? FibroGen received 343 more outperform votes than Incannex Healthcare when rated by MarketBeat users. CompanyUnderperformOutperformFibroGenOutperform Votes34360.71% Underperform Votes22239.29% Incannex HealthcareN/AN/A Does the media favor FGEN or IXHL? In the previous week, FibroGen had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 5 mentions for FibroGen and 4 mentions for Incannex Healthcare. FibroGen's average media sentiment score of 0.80 beat Incannex Healthcare's score of 0.75 indicating that FibroGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroGen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incannex Healthcare 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, FGEN or IXHL? Incannex Healthcare has lower revenue, but higher earnings than FibroGen. Incannex Healthcare is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$147.75M0.24-$284.23M-$1.23-0.28Incannex Healthcare$10K13,267.32-$18.46M-$1.39-1.50 Which has more risk & volatility, FGEN or IXHL? FibroGen has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 8.11, meaning that its share price is 711% more volatile than the S&P 500. SummaryFibroGen beats Incannex Healthcare on 10 of the 15 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.27M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.2810.78126.3117.81Price / Sales0.24243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book-0.195.474.684.68Net Income-$284.23M$153.61M$119.54M$226.08M7 Day Performance-5.38%-2.00%-1.83%-1.04%1 Month Performance-6.54%-7.46%-3.60%1.04%1 Year Performance-28.47%31.82%31.91%26.28% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen2.4565 of 5 stars$0.35flatN/A-33.8%$35.27M$147.75M-0.28486Analyst RevisionGap UpIXHLIncannex Healthcare1.3608 of 5 stars$2.09-2.8%N/A+132.2%$136.48M$10,000.000.003Gap UpSGMTSagimet Biosciences1.7952 of 5 stars$4.52+2.5%$21.60+377.9%+50.2%$135.28M$2M0.008PBYIPuma Biotechnology4.4109 of 5 stars$2.84+3.6%$7.00+146.5%-27.0%$134.50M$235.60M5.92185Analyst ForecastPositive NewsSKYESkye Bioscience1.2808 of 5 stars$4.28-1.4%$18.67+336.1%+152.9%$131.67MN/A0.0011Insider TradeTELOTelomir PharmaceuticalsN/A$4.20-5.4%N/AN/A$131.47MN/A0.001VTYXVentyx Biosciences2.4784 of 5 stars$1.72-3.4%$10.00+481.4%-27.1%$125.86MN/A0.0073RPTXRepare Therapeutics2.672 of 5 stars$2.84-1.4%$10.00+252.1%-44.7%$122.43M$51.13M0.00180CNTXContext Therapeutics2.0666 of 5 stars$1.63-1.2%$6.25+283.4%+81.1%$122.25MN/A-1.817MCRBSeres Therapeutics3.8903 of 5 stars$0.81+19.0%$5.08+524.6%-16.1%$117.54M$126.32M0.00233Analyst UpgradeHigh Trading VolumeGLPGGalapagos1.2816 of 5 stars$25.64-3.9%$30.75+19.9%-31.4%$1.69B$259.40M0.001,123Analyst DowngradeShort Interest ↓Gap DownHigh Trading Volume Related Companies and Tools Related Companies Incannex Healthcare Competitors Sagimet Biosciences Competitors Puma Biotechnology Competitors Skye Bioscience Competitors Telomir Pharmaceuticals Competitors Ventyx Biosciences Competitors Repare Therapeutics Competitors Context Therapeutics Competitors Seres Therapeutics Competitors Galapagos Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FGEN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FGEN Stock Alerts